Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026

Freenome reports improved sensitivity for its colorectal cancer blood test, but financial impact remains unclear.

What the company is saying

Freenome is highlighting new clinical data for its updated SimpleScreen CRC blood-based screening test, emphasizing significant improvements in sensitivity for detecting advanced precancerous lesions and colorectal cancer. The company frames these results as the highest reported to date for non-invasive blood tests in a pivotal clinical study, though no external benchmarks are provided. CEO Aaron Elliott, Ph.D., stresses the importance of ongoing assay and algorithm refinements as part of a broader up-versioning strategy, suggesting this iterative approach will benefit both colorectal and future multi-cancer screening products. The narrative is focused on technical achievement and the potential to expand access to screening for millions of unscreened Americans. The announcement also notes the recent FDA approval (July 2026) and commercial launch (late September 2026) in the United States through Abbott Cancer Diagnostics. The tone is confident and forward-looking, but the company does not discuss adoption rates, reimbursement, or financial outcomes.

What the data suggests

The updated SimpleScreen CRC test demonstrated 18.2% sensitivity for detecting advanced precancerous lesions, up from 13.7% in the original PREEMPT CRC study. Sensitivity for advanced precancerous lesions with high-grade dysplasia improved to 41.9%, compared to 30.5% previously. For colorectal cancer detection, the updated test achieved 80.4% sensitivity. Specificity for no findings on colonoscopy was 90% after adjusting for U.S. Census age and sex distribution. These improvements are material and suggest technical progress in assay performance. However, the claim of 'highest reported to date' sensitivity is not substantiated with comparative data. The announcement does not provide any financial figures, adoption metrics, or operational data related to sales, reimbursement, or market penetration. The evidence supports clinical advancement, but the business impact is not quantifiable from the disclosed information.

Analysis

The announcement is generally positive in tone, highlighting improved clinical performance metrics for the updated SimpleScreen CRC test and referencing recent FDA approval and commercial launch. The majority of key claims are realised and supported by specific sensitivity and specificity data, with only a minority of statements being forward-looking or aspirational (e.g., potential for broader pipeline impact and future screening expansion). The language is somewhat inflated in places, particularly where the company claims 'highest reported to date' sensitivity without providing external benchmarks or comparative data. There is no mention of financial results, adoption rates, or profitability, which limits the strength of the investment signal. However, the absence of large capital outlay or long-dated benefit projections means the hype is contained. The data supports a weak_positive signal due to clear clinical progress, but the lack of financial disclosure and some superlative language prevent a stronger rating.

Risk flags

• ●The absence of adoption, reimbursement, or sales data means there is no visibility into whether improved clinical performance will translate into commercial success. Without evidence of market uptake, the financial impact remains speculative.
• ●The company's claim of 'highest reported to date' sensitivity is not backed by external benchmarks or peer comparisons, raising questions about the strength of this superlative and the true competitive position.
• ●Reliance on iterative assay and algorithm improvements introduces ongoing execution risk, as future upgrades may not yield similar gains or may face regulatory or technical hurdles.

Bottom line

Freenome's updated SimpleScreen CRC test shows clear technical progress, with sensitivity for advanced precancerous lesions and colorectal cancer detection improving to 18.2% and 80.4%, respectively. The test is now FDA-approved and commercially available in the United States through Abbott Cancer Diagnostics. While the clinical data is robust, the announcement does not address whether these improvements are driving actual market adoption, reimbursement, or revenue growth. The lack of financial or operational metrics limits the ability to assess the business impact or investment case. Investors should focus on future disclosures that quantify adoption, sales, or payer coverage to determine if clinical gains are translating into commercial value. The most important takeaway is that while technical milestones are being met, the commercial story is still unproven.

Announcement summary

(NASDAQ:FRNM) Freenome, Inc. announced it will present late-breaking data on an updated version of its SimpleScreen™ CRC blood-based screening test at the American College of Gastroenterology (ACG) 2026 Annual Meeting in Nashville. The company conducted a pivotal clinical validation study to assess the performance of assay and algorithm improvements for the updated SimpleScreen CRC test. The FDA approved the first-generation version of SimpleScreen CRC in July 2026, and the test was commercially launched in late September in the United States by Freenome’s partner Abbott Cancer Diagnostics. The updated test demonstrated 18.2% sensitivity for detecting advanced precancerous lesions (APLs), compared to 13.7% sensitivity in the original PREEMPT CRC study. Sensitivity for APLs with high-grade dysplasia (HGD) improved to 41.9% in the updated test, compared to 30.5% previously. The sensitivity results for APLs and APLs with HGD in this study are the highest reported to date for any non-invasive screening blood test in a prospective registrational pivotal clinical study. Sensitivity was also improved for all APL subtypes, including villous or tubulovillous; adenomas ≥ 10 mm; sessile serrated lesions/polyps ≥ 10 mm; and traditional serrated adenomas. The updated test demonstrated 80.4% sensitivity for detecting colorectal cancer (CRC). The results were adjusted to the age and sex distribution of the U.S. Census to better reflect the intended use population. Specificity for no findings on colonoscopy was 90%. Aaron Elliott, Ph.D., CEO of Freenome, stated that the results suggest the blood-based screening test may detect precancerous lesions with clinically meaningful sensitivity and highlighted the importance of continual assay and algorithm improvements. Aasma Shaukat, M.D., M.P.H., professor of medicine at NYU Grossman School of Medicine and co-lead principal investigator on the PREEMPT CRC study, will present the detailed results. The presentation is titled 'Improved Sensitivity for Advanced Precancerous Lesions (APLs) Demonstrated in Clinical Validation of an Updated Colorectal Cancer (CRC) Screening Blood Test in an Average-Risk Population' and is scheduled for Wednesday, Oct. 14, from 9:10-9:20 am during Plenary Session 4B: Liver, Esophagus, CRC, IBD.

Disagree with this article?